June 4, 2018New England Journal of Medicine1,422 citationsOpen Access
PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma
View Full Paper
Key Points
Key points are not available for this paper at this time.
Abstract
Among patients with advanced cutaneous squamous-cell carcinoma, cemiplimab induced a response in approximately half the patients and was associated with adverse events that usually occur with immune checkpoint inhibitors. (Funded by Regeneron Pharmaceuticals and Sanofi; ClinicalTrials.gov numbers, NCT02383212 and NCT02760498 .).